Abionyx Pharma annual debt-to-equity ratio
2019
2020
2021
2022
2023
2024
2025
Abionyx Pharma Debt-to-Equity Ratio Growth & History (ABNX)
Abionyx Pharma's debt-to-equity ratio was 0.84 for fiscal 2025.
View full Abionyx Pharma company overviewAbionyx Pharma annual debt-to-equity ratio history
| Fiscal year | Period ended | Debt-to-equity ratio | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 0.84 | 0.48 | +129.87% |
| 2024 | 2024-12-31 | 0.37 | −0.06 | −14.27% |
| 2023 | 2023-12-31 | 0.43 | −0.13 | −23.55% |
| 2022 | 2022-12-31 | 0.56 | 0.16 | +38.83% |
| 2021 | 2021-12-31 | 0.40 | 0.40 | +11036.81% |
| 2020 | 2020-12-31 | 0.00 | −0.01 | −70.92% |
| 2019 | 2019-12-31 | 0.01 | — | — |
Abionyx Pharma quarterly debt-to-equity ratio
Q4.24
Q4.25
| Fiscal quarter | Period ended | Debt-to-equity ratio | Change | YoY change |
|---|---|---|---|---|
| Q4 2025 | 2025-12-31 | 0.84 | 0.48 | +129.87% |
| Q4 2024 | 2024-12-31 | 0.37 | — | — |
Abionyx Pharma debt-to-equity ratio trends
Over the last five fiscal years, Abionyx Pharma's debt-to-equity ratio increased from 0.00 to 0.84, a change of 0.84. The latest reported quarter, Q4 2025, shows 0.84.
About the metric
What the debt-to-equity ratio means
The debt-to-equity ratio compares interest-bearing debt with shareholders’ equity. It helps show how much debt financing a company uses relative to its accounting equity, but useful comparison levels vary by industry.
Calculation and source
How debt-to-equity is calculated
TickerStat calculates debt-to-equity as total interest-bearing debt divided by reported shareholders’ equity for the same balance-sheet date. Total liabilities are not treated as debt, and periods with non-positive equity are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Abionyx Pharma source filings ↗